Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
=== Fetal development impacts === Multiple epidemiological studies of people living in Europe, the United States, and China have linked in utero exposure to PAHs, through air pollution or parental occupational exposure, with poor fetal growth, reduced immune function, and poorer neurological development, including lower IQ.
According to James B. Harrod humankind first developed religious and spiritual beliefs during the Middle Paleolithic or Upper Paleolithic. Controversial scholars of prehistoric religion and anthropology, James Harrod and Vincent W. Fallio, have recently proposed that religion and spirituality (and art) may have first arisen in Pre-Paleolithic chimpanzees or Early Lower Paleolithic (Oldowan) societies. According to Fallio, the common ancestor of chimpanzees and humans experienced altered states of consciousness and partook in ritual, and ritual was used in their societies to strengthen social bonding and group cohesion. Middle Paleolithic humans' use of burials at sites such as Krapina, Croatia (c. 130,000 BP) and Qafzeh, Israel (c. 100,000 BP) have led some anthropologists and archaeologists, such as Philip Lieberman, to believe that Middle Paleolithic humans may have possessed a belief in an afterlife and a "concern for the dead that transcends daily life". Cut marks on Neanderthal bones from various sites, such as Combe-Grenal and Abri Moula in France, suggest that the Neanderthals—like some contemporary human cultures—may have practiced ritual defleshing for (presumably) religious reasons. According to recent archaeological findings from Homo heidelbergensis sites in Atapuerca, humans may have begun burying their dead much earlier, during the late Lower Paleolithic; but this theory is widely questioned in the scientific community.
I realized that for a long time I had been holding onto this whole dogma of nonracism almost like a religion ... But in the course of that debate I began to feel there was a lot lacking in the proponents of the nonracist idea ... they had this problem, you know, of superiority, and they tended to take us for granted and wanted us to accept things that were second-class. They could not see why we could not consider staying in that church, and I began to feel that our understanding of our own situation in this country was not coincidental with that of these liberal whites.
Sources: en.wikipedia.org
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 28 August A Short History of the Future: Spaceship, how space ships were viewed at cinema, and that the US space programme was largely started by Wernher von Braun, when making documentary programmes at Walt Disney; the American public needed to be convinced of the possibilities of space travel - as it would be publicly funded; Jesco Von Puttkamer of NASA; technology historical writer Frederick I. Ordway III; von Braun had first attempted a rocket launch in 1937, but it exploded; on 3 October 1942, his first successful rocket was the first man-made supersonic craft; there were 3,165 V-2 successful launches during the war; much 1950s popular space diagrams were drawn by Chesley Bonestell, which drew the attention of Walt Disney and producer Ward Kimball, who subsequently made the 1955 television episodes Man in Space and Man and the Moon, featuring Wernher von Braun, where von Braun demonstrated his XR-1 craft; health effects of space were demonstrated by former Luftwaffe fighter pilot and physicist Heinz Haber, later a well-known German television presenter; Star Trek: The Original Series was not popular when first shown, but was hugely popular after 1972 when it was repeated; consequently, the first space shuttle was named Enterprise, and when the shuttle was displayed in California on 17 September 1976, it was attended by the full cast of Star Trek, with the theme music also being played; Beverly Thurmond, NASA food scientist; Laura Louviere of NASA.
== Formulation of the rule == This rule is derived from the fact that, perhaps coincidentally, for the most common chemical elements in neutral organic compounds (hydrogen, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur, and the halogens), elements with even numbered nominal masses form even numbers of covalent bonds, while elements with odd numbered nominal masses form odd numbers of covalent bonds, with the exception of nitrogen, which has a nominal (or integer) mass of 14, but has a valency of 3. The nitrogen rule is only true for neutral structures in which all of the atoms in the molecule have a number of covalent bonds equal to their standard valency (counting each sigma bond and pi bond as a separate covalent bond for the purposes of the calculation). Therefore, the rule is typically only applied to the molecular ion signal in the mass spectrum. Mass spectrometry generally operates by measuring the mass of ions. If the measured ion is generated by creating or breaking a single covalent bond (such as protonating an amine to form an ammonium center or removing a hydride from a molecule to leave a positively charged ion) then the nitrogen rule becomes reversed (odd numbered masses indicate even numbers of nitrogens and vice versa). However, for each consecutive covalent bond that is broken or formed, the nitrogen rule again reverses.
During continuous weekly intramuscular injections of CPA in men with prostate cancer, mean levels of CPA roughly doubled from 170 ng/mL (408 nmol/L) after the first injection to 310 ng/mL (744 nmol/L) after the fifth injection, and were projected to increase to 350 to 400 ng/mL (840–960 nmol/L) after around 8 to 12 injections. The area-under-the-curve (AUC; total exposure) levels of CPA with 100 mg/day oral CPA and 300 mg/week intramuscular CPA may be approximately equivalent.
Sources: en.wikipedia.org
District of Hanover: formed in 2001 from the rural district of Hanover and the district-free city of Hanover. Regionalverband (district association) of Saarbrücken: formed in 2008 from the Stadtverband Saarbrücken (city association of Saarbrücken), which was formed in 1974. City region of Aachen: formed in 2009 from the rural district of Aachen and the district-free city of Aachen.
Educating patients who have rheumatoid arthritis has shown a positive effect on how patients engage in their plan of care; the patient will be aware of fatigue, activity limitations, and pain and know possible side effects of how to manage this pain. Lack of knowledge can often lead to fear and limit adherence. Intervention by physical therapists plays a key role in offering proper tools for self-management, motivation in activities of daily living, and any assistive device use if needed. Patients will be assisted in managing neurological impairments and musculoskeletal stiffness to maximize strength and function. Encouraging patients to balance physical activity with their everyday living can prevent further joint damage and provide a sense of control. The use of extra-depth shoes and molded insoles may reduce pain during weight-bearing activities such as walking. Insoles may also prevent the progression of bunions.
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease. Cinnarizine is one of the leading causes of drug-induced parkinsonism. Cinnarizine was first synthesized as R1575 by Janssen Pharmaceutica in 1955. The nonproprietary name is derived from the cinnamyl substituent on the free nitrogen atom of the benzhydrylpiperazine core, combined with the generic ending "-rizine" for "antihistaminics/cerebral (or peripheral) vasodilators". It is not available in the United States or Canada. It has also been cited as one of the most used drugs for seasickness within the British Royal Navy.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.